Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPALAN vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin at the presynaptic terminal.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder,Panic disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Hypertension
100 mg orally twice daily
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life is 12-14 hours in adults with normal renal function; prolonged to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 60 hours in severe renal impairment (Cr Cl <30 m L/min).
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Hepatic via CYP2D6 and CYP3A4; active metabolite N-desmethylserpalan.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal elimination (60-70% unchanged drug), with 20-30% biliary/fecal excretion as metabolites; less than 10% excreted unchanged in feces.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Approximately 85-90% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
1.2-1.8 L/kg, indicating extensive tissue distribution (e.g., liver, kidneys, and lungs); higher Vd in obese patients.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: 75-85% due to first-pass metabolism; IM: 90-98%; rectal: 50-70%.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
GFR ≥ 60 m L/min: no adjustment; GFR 30-59 m L/min: 50 mg once daily; GFR < 30 m L/min: avoid use
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily; Child-Pugh C: contraindicated
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not established for patients < 18 years
Not established; avoid use in children.
Maximum 50 mg once daily due to increased sensitivity and renal impairment risk
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
Suicidal thoughts and behaviors: Increased risk in children, adolescents, and young adults during initial treatment.
None
Serotonin syndrome with concomitant serotonergic drugs; risk of bleeding with NSAIDs/anticoagulants; activation of mania/hypomania; bone fracture risk in elderly; hyponatremia; QT prolongation at high doses.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to serpalan; concurrent use of MAOIs or linezolid; concurrent use of pimozide; use of MAOIs within 14 days.
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid concurrent use of alcohol; may worsen central nervous system effects. No specific food restrictions; take with or without food. Grapefruit juice has no significant interaction.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: increased risk of structural anomalies including cardiac defects (FDA category C; animal studies show teratogenicity at clinically relevant doses). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm birth. Late third trimester: neonatal withdrawal syndrome and respiratory depression.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Excreted into breast milk (M/P ratio 0.9). Not recommended during breastfeeding due to potential adverse effects on infant including sedation, poor feeding, and withdrawal. Consider alternative therapy.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Due to increased plasma volume and hepatic metabolism, dose may need to be increased by 20-30% in the second and third trimesters. Monitor trough levels and adjust to maintain therapeutic range. Postpartum, decrease dose to prepregnancy levels within 48 hours.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
SERPALAN is a selective serotonin reuptake inhibitor (SSRI) used for major depressive disorder. Monitor for serotonin syndrome, especially when co-prescribed with other serotonergic drugs. Initiate at 20 mg daily; titrate to 40 mg after 4 weeks if needed. Do not abruptly discontinue; taper gradually to avoid withdrawal symptoms. Use with caution in patients with hepatic impairment (dose reduction recommended). Avoid MAOIs within 14 days.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take this medication at the same time each day, with or without food.,Do not stop taking this medication suddenly; consult your doctor for a tapering schedule.,It may take 2–4 weeks to feel the full benefit; continue taking even if you do not notice immediate improvement.,Notify your doctor if you experience new or worsening anxiety, agitation, or suicidal thoughts.,Avoid alcohol while taking this medication.,Do not take other medications, including over-the-counter drugs, without consulting your doctor.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPALAN vs ALDORIL 25, answered by our medical review team.
SERPALAN is a Antihypertensive that works by Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin at the presynaptic terminal.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPALAN and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPALAN is: 100 mg orally twice daily. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPALAN and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPALAN is classified as Category C. First trimester: increased risk of structural anomalies including cardiac defects (FDA category C; animal studies show teratogenicity at clinically relevant doses). Second and thir. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.